Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Inhibiting Integrin β8 to Differentiate and Radiosensitize Glioblastoma-Initiating Cells.

Malric L, Monferran S, Delmas C, Arnauduc F, Dahan P, Boyrie S, Deshors P, Lubrano V, Da Mota DF, Gilhodes J, Filleron T, Siegfried A, Evrard S, Kowalski-Chauvel A, Moyal EC, Toulas C, Lemarié A.

Mol Cancer Res. 2019 Feb;17(2):384-397. doi: 10.1158/1541-7786.MCR-18-0386. Epub 2018 Sep 28.

PMID:
30266751
2.

EANO guidelines for the diagnosis and treatment of ependymal tumors.

Rudà R, Reifenberger G, Frappaz D, Pfister SM, Laprie A, Santarius T, Roth P, Tonn JC, Soffietti R, Weller M, Moyal EC.

Neuro Oncol. 2018 Mar 27;20(4):445-456. doi: 10.1093/neuonc/nox166. Review.

3.

A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.

Deutsch E, Moyal EC, Gregorc V, Zucali PA, Menard J, Soria JC, Kloos I, Hsu J, Luan Y, Liu E, Vezan R, Graef T, Rivera S.

Oncotarget. 2016 Dec 24;8(34):56199-56209. doi: 10.18632/oncotarget.14147. eCollection 2017 Aug 22.

4.

EANO guidelines for the diagnosis and treatment of meningiomas.

Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, von Deimling A, Stavrinou P, Lefranc F, Lund-Johansen M, Moyal EC, Brandsma D, Henriksson R, Soffietti R, Weller M.

Lancet Oncol. 2016 Sep;17(9):e383-91. doi: 10.1016/S1470-2045(16)30321-7. Epub 2016 Aug 30. Review.

5.

Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation.

Khalifa J, Tensaouti F, Chaltiel L, Lotterie JA, Catalaa I, Sunyach MP, Ibarrola D, Noël G, Truc G, Walker P, Magné N, Charissoux M, Ken S, Peran P, Berry I, Moyal EC, Laprie A.

Eur Radiol. 2016 Nov;26(11):4194-4203. Epub 2016 Feb 2.

PMID:
26843012
6.

Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.

Ken S, Deviers A, Filleron T, Catalaa I, Lotterie JA, Khalifa J, Lubrano V, Berry I, Péran P, Celsis P, Moyal EC, Laprie A.

J Neurooncol. 2015 Sep;124(3):465-73. doi: 10.1007/s11060-015-1860-8. Epub 2015 Jul 19.

PMID:
26189058
7.

Int6/eIF3e is essential for proliferation and survival of human glioblastoma cells.

Sesen J, Cammas A, Scotland SJ, Elefterion B, Lemarié A, Millevoi S, Mathew LK, Seva C, Toulas C, Moyal EC, Skuli N.

Int J Mol Sci. 2014 Jan 29;15(2):2172-90. doi: 10.3390/ijms15022172.

8.

The β5/focal adhesion kinase/glycogen synthase kinase 3β integrin pathway in high-grade osteosarcoma: a protein expression profile predictive of response to neoadjuvant chemotherapy.

Le Guellec S, Moyal EC, Filleron T, Delisle MB, Chevreau C, Rubie H, Castex MP, de Gauzy JS, Bonnevialle P, Gomez-Brouchet A.

Hum Pathol. 2013 Oct;44(10):2149-58. doi: 10.1016/j.humpath.2013.03.020. Epub 2013 Jul 8.

PMID:
23845472
9.

[Optimization of the radiotherapy for the gliomas: hopes and research axis for the next future].

Moyal EC.

Rev Neurol (Paris). 2011 Oct;167(10):656-60. doi: 10.1016/j.neurol.2011.07.001. Epub 2011 Sep 1. Review. French.

PMID:
21889179
10.

Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study.

Laprie A, Catalaa I, Cassol E, McKnight TR, Berchery D, Marre D, Bachaud JM, Berry I, Moyal EC.

Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):773-81. doi: 10.1016/j.ijrobp.2007.10.039.

PMID:
18262090
11.

Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme.

Moyal EC, Laprie A, Delannes M, Poublanc M, Catalaa I, Dalenc F, Berchery D, Sabatier J, Bousquet P, De Porre P, Alaux B, Toulas C.

Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1396-401. Epub 2007 Jun 14.

PMID:
17570606

Supplemental Content

Loading ...
Support Center